Creso Pharma’s Mernova receives esteemed award

|

Published 17-MAY-2021 11:52 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

In a development that will effectively make Creso Pharma Limited (ASX:CPH, FRA: 1X8) wholly-owned Canadian subsidiary Mernova Medicinal Inc. one of a select group of licensed cannabis producers the group has been awarded Craft Designation by the Ontario Cannabis Store (OCS).

The OCS is a crown agency solely owned by the Province of Ontario, and it reports directly to the Ministry of Finance, being the province’s only retailer and wholesaler of legal recreational cannabis.

The OCS has created a specific category for craft cannabis products available to consumers in Ontario.

To qualify, dried-flower and pre-roll products must be hand-trimmed, hang-dried and hand-packaged.

Mernova’s managing director Jack Yu was praiseworthy of his operational team in terms of their commitment to optimum quality production control in saying, “Our focus has always been on quality over all else and being awarded OCS Craft Designation is a direct result of this strategy.

"To be one of the only companies to be awarded OCS Craft Designation in Ontario is a major validation of the hard work and effort put in by our operations team, and it reflects the resulting artisanal quality of our products.

‘’We do things the right way, combining science and artisanal methods to produce some of the finest cannabis available.

‘’We don’t compromise on quality, and we’re becoming recognised within the industry because of it.’’

Award is expected to provide competitive advantages

This designation is an important achievement for Mernova and will provide Creso Pharma with much broader visibility in a competitive market.

It also highlights the superior quality of Mernova’s products as the company continues to achieve strong sales growth across Ontario.

On this note, Yu said, "We are confident that this new category will help further differentiate us from the competition, enhance our brand, and provide increased brand exposure and brand awareness, which should result in much broader visibility within the market.”

Currently, Mernova’s HPG13, Lemon Haze, and Clementine Punch strains are sold out across multiple dispensaries in the province.

Ontario represents a large addressable market for Creso Pharma, and as it is one of the largest recreational cannabis markets in Canada there is an expectation of Mernova achieving ongoing growth through the region.

Ritual Green products are currently available to over 600 stores in Ontario, while also being available to the public directly through the OCS online sales platform.

Management is continuing to monitor potential patterns and shifts in the distribution of cannabis in Ontario in order to adjust to the varying dynamics.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X